| everolimus / Generic mfg. |
| Completed | 3 | 320 | | | Professor Allan R. Glanville, Novartis | Heart Lung, Bilateral Lung and Single Lung Transplant recipients | | | | |
NCT00097968: Safety/Efficacy of Everolimus and Neoral® in Adult Cardiac Transplant Patients With Established Allograft Vasculopathy |
|
|
| Completed | 3 | | US | everolimus | Novartis Pharmaceuticals | Graft Rejection | 04/05 | | | |
NCT00531063: This is a Two-year Follow-up Study to Evaluate the Long-term Safety, Tolerability and Efficacy of 2 Different Doses of Everolimus |
|
|
| Completed | 3 | 237 | Europe | Everolimus (RAD001) | Novartis Pharmaceuticals | Renal Transplantation | 08/05 | | | |
NCT00531440: This is a 2-year Follow-up Study to Evaluate the Long-term Effects in Patients Who Completed the Study CRAD001A2307. |
|
|
| Completed | 3 | 256 | Europe | Everolimus (RAD001) | Novartis Pharmaceuticals | Renal Transplantation | 08/05 | | | |
NCT00170833: Safety, Tolerability and Efficacy of Everolimus With Lower Versus Higher Levels of Tacrolimus in de Novo Renal Transplant Patients |
|
|
| Completed | 3 | 80 | US | Everolimus | Novartis Pharmaceuticals | Renal Transplantation | 11/05 | | | |
NCT00170794: Renal Safety of Everolimus in Addition to Cyclosporine Microemulsion in Cardiac Transplant Recipients. |
|
|
| Completed | 3 | | Canada | Everolimus (RAD001) | Novartis Pharmaceuticals | Cardiac Transplantation | 07/06 | | | |
| Completed | 3 | 199 | US, Canada, Europe, RoW | Everolimus (Certican) | Novartis Pharmaceuticals | Heart Transplantation | 01/07 | 01/07 | | |
| Unknown status | 3 | 484 | Europe | Everolimus | German Heart Institute, Novartis | Coronary Artery Disease, Coronary Restenosis | | | | |
NCT00098241: Safety & Efficacy of Certican in Pediatric de Novo Renal Transplant Patients |
|
|
| Completed | 3 | 45 | US, Europe | Certican | Novartis Pharmaceuticals | Kidney Transplantation | 03/07 | 03/07 | | |
| Completed | 3 | 176 | Europe | Everolimus | Novartis Pharmaceuticals | Heart Transplantation | 05/07 | | | |
| Completed | 3 | 145 | Europe | Everolimus, Certican, RAD001, Neoral®/Prograf®, Calcineurin inhibitors (CNI), Neoral/Prograf, Mycophenolate acid (MPA)/ Azathioprine (AZA), Myfortic/Cellecept, Steroids | Novartis Pharmaceuticals | Liver Transplantation | 11/07 | 11/07 | | |
RECORD-1, NCT00410124 / 2006-002070-21: RAD001 Plus Best Supportive Care (BSC) Versus BSC Plus Placebo in Patients With Metastatic Carcinoma of the Kidney Which Has Progressed After Treatment With Sorafenib and/or Sunitinib |
|
|
| Completed | 3 | 416 | Japan, US, Canada, Europe, RoW | RAD001, Everolimus, Placebo | Novartis Pharmaceuticals | Metastatic Renal Cell Carcinoma | 02/08 | 10/11 | | |
|
|
|
|
|
|
|
|
|
CERTES02, NCT00154284: Everolimus in a Cyclosporine Microemulsion-free Regimen Compared to a Low-dose Cyclosporine Microemulsion Regimen, in de Novo Kidney Transplant Patients |
|
|
| Completed | 3 | 114 | NA | Everolimus (Certican), Certican, Cyclosporine (Neoral), Neoral, Steroid, Prednisone, Basiliximab (Simulect), Simulect | Novartis | Organ Transplantation, Renal Transplantation | 07/08 | 07/08 | | |
EVEREST, NCT01276457: Everolimus in Combination With Cyclosporine Microemulsion in de Novo Renal Transplant Recipients |
|
|
| Completed | 3 | 223 | Europe | Everolimus 0.25 and 0.75 mg tablets, Cyclosporine very low dose (150-300 ng/mL) microemulsion, Neoral, Cyclosporine low dose (350-500 ng/mL) microemulsion | Novartis Pharmaceuticals | Transplantation Infection | 02/09 | 02/09 | | |
NCT00425308: Efficacy and Safety of Everolimus in Combination With Cyclosporine Microemulsion Versus Everolimus in Combination With Enteric-coated Mycophenolate Sodium (EC-MPS), in Adult Renal Transplant Patients in Maintenance. |
|
|
| Completed | 3 | 30 | Europe | Everolimus + Cyclosporine, Cyclosporine Microemulsion, Neoral, Everolimus + Enteric-coated Mycophenolate Sodium (EC-MPS), Myfortic, Steroids | Novartis Pharmaceuticals | Renal Transplantation | 05/09 | | | |
NCT00251004 / 2005-002854-22: Efficacy and Safety Study of Everolimus Plus Reduced Cyclosporine Versus Mycophenolic Acid Plus Cyclosporine in Kidney Transplant Recipients |
|
|
| Completed | 3 | 833 | US | Everolimus, Certican, Zotress, Mycophenolic Acid (MPA), Myfortic, Cyclosporine A (CsA), Neoral, Basiliximab, Simulect, Corticosteroids | Novartis | Kidney Transplantation, Graft Rejection | 08/09 | 10/09 | | |
| Completed | 3 | 410 | Japan, US, Canada, Europe, RoW | Everolimus, RAD001, Everolimus Placebo | Novartis Pharmaceuticals | Advanced Neuroendocrine Tumors of Pancreatic Origin | 02/10 | 03/14 | | |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
| Completed | 3 | 429 | US, Canada, Europe, RoW | Octreotide, Sandostatin LAR® Depot, Placebo, Everolimus, RAD001 | Novartis Pharmaceuticals | Carcinoid Tumor, Malignant Carcinoid Syndrome | 04/10 | 06/13 | | |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
NCT00658320: Concentration Controlled Everolimus With Reduced Dose Cyclosporine Versus Mycophenolate Mofetil With Standard Dose Cyclosporine in de Novo Renal Transplant Adult Recipients Treated With Basiliximab and Corticosteroids |
|
|
| Completed | 3 | 122 | Japan | Everolimus, Certican, Mycophenolate mofetil (MMF), MMF, Basiliximab, Cyclosporine A, Neoral®, Corticosteroid | Novartis | Kidney Transplantation | 08/10 | 05/12 | | |
EXIST-1, NCT00789828 / 2007-006997-27: Efficacy and Safety of Everolimus (RAD001) in Patients of All Ages With Subependymal Giant Cell Astrocytoma Associated With Tuberous Sclerosis Complex (TSC) |
|
|
| Completed | 3 | 117 | US, Canada, Europe, RoW | Everolimus, RAD001, Placebo | Novartis Pharmaceuticals | Tuberous Sclerosis, Subependymal Giant Cell Astrocytoma | 03/11 | 10/14 | | |
|
|
2004-000849-38: A Phase 3, randomized, double-blind, placebo-controlled multi-center study of RAD001 in combination with letrozole (Femara®) to investigate the value of adding RAD001 to letrozole as a first-line therapy in postmenopausal women with advanced breast cancer |
|
|
| Terminated | 3 | 1200 | Europe | RAD001, Femara, RAD001, FEM345, Tablet | Novartis Pharma Services AG | The treatment of advanced breast cancer aims at reducing tumor size, slowing progression and metastasis and reducing complications such as fatigue, bone fracture and hypercalcemia. Women with tumors which are hormone dependent are candidates for endocrine therapies which have been shown to effectively delay disease progression and are much less toxic than cytotoxic chemotherapy. This study investigates the benefit of combining the antiendocrine drug letrozole (Femara®) and everolimus (RAD001). | | | | |
EXIST-2, NCT00790400 / 2008-002113-48: Efficacy and Safety of RAD001 in Patients Aged 18 and Over With Angiomyolipoma Associated With Either Tuberous Sclerosis Complex (TSC) or Sporadic Lymphangioleiomyomatosis (LAM) |
|
|
| Completed | 3 | 118 | Japan, US, Canada, Europe, RoW | Everolimus (RAD001), RAD001, Everolimus Placebo | Novartis Pharmaceuticals | Tuberous Sclerosis Complex (TSC), Lymphangioleiomyomatosis (LAM) | 06/11 | 11/15 | | |
|
|
|
|
|
|
|
|
| Completed | 3 | 721 | US, Canada, Europe, RoW | everolimus, Zortress®, Certican®, mycophenolate mofetil, Cellcept®, cyclosporine, Neoral®, corticosteroids | Novartis Pharmaceuticals | Graft Rejection | 07/11 | 07/11 | | |
| Completed | 3 | 2600 | Europe | epirubicin - cyclophosphamide / docetaxel, epirubicin - cyclophosphamide / docetaxel + bevacizumab, paclitaxel, paclitaxel + everolimus (RAD001), epirubicin - cyclophosphamide / docetaxel + trastuzumab, epirubicin - cyclophosphamide / docetaxel + lapatinib | German Breast Group, AGO Study Group | Breast Cancer | 08/11 | 10/15 | | |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
NCT00402532: Immunosuppressive Therapy With Certican (Everolimus) After Lung Transplantation |
|
|
| Completed | 3 | 190 | Europe | Everolimus, Certican, Mycophenolatmofetil, Cellcept | Hannover Medical School, Novartis Pharmaceuticals | Lung Transplantation | 11/11 | 12/11 | | |
2004-001290-25: A 3-Year Randomised, Open Label, Multi-Centre Investigator Driven Study Comparing de Novo Enteric Coated Mycophenolate Sodium with Delayed Onset Everolimus, Both Arms in Combination with Cyclosporin (using C2 monitoring) and Corticosteroids for the Prevention of Bronchiolitis Obliterans Syndrome in Heart-Lung, Bilateral Lung and Single Lung Transplant Recipients. |
|
|
| Completed | 3 | 320 | Europe | Myfortic, Certican 0,5, Certican 0,75mg, ERL080, RAD001, Tablet, Certican, Myfortic | St Vincent's Hospital, Prof Allan Glanville, St Vincents Hospital, St Vincent’s Hospital, Sydney, Australia, Hospital Vall d Hebron | Heart-Lung, bilateral lung and single lung transplant recipientsICD Classification: K01-K01.9, E53.9+Z94.1, E53.9+Z94.2, E53.9+Z94.3 | | | | |
RAD, NCT00622869 / 2007-001821-85: Efficacy and Safety of Concentration-controlled Everolimus to Eliminate or to Reduce Tacrolimus Compared to Tacrolimus in de Novo Liver Transplant Recipients |
|
|
| Completed | 3 | 719 | US, Canada, Europe, RoW | Tacrolimus (reduced tacrolimus), FK-506, fujimycin, Prograf, Advagraf, Protopic, Tacrolimus (tacrolimus elimination), Tacrolimus (tacrolimus control), Everolimus (reduced tacrolimus), RAD-001, Zortress, Certican, Afinitor, Everolimus (tacrolimus elimination), Corticosteroids | Novartis Pharmaceuticals | Liver Transplantation | 04/12 | 04/12 | | |
PROTECT, NCT00966836: Prevention of Transplant Atherosclerosis With Everolimus and Anti-cytomegalovirus Therapy |
|
|
| Unknown status | 3 | 100 | Europe | Pre-emptive strategy with valganciclovir plus everolimus, Prophylaxis with valganciclovir plus mycophenolate, Prophylaxis with valganciclovir plus everolimus, Pre-emptive mycophenolate | University of Bologna | Heart Transplantation, Cardiac Allograft Vasculopathy, Cytomegalovirus Infection | 04/12 | | | |
2012-001099-13: Extension study to the expanded access study of everolimus in patients with advanced neuroendocrine tumors |
|
|
| Completed | 3 | 40 | Europe | Tablet, Afinitor, Afitinor | Novartis Pharma GmbH, Novartis Pharma GmbH | advanced neuroendocrine tumors of gastrointestinal or lung origin, advanced neuroendocrine tumors of gastrointestinal or lung origin, Diseases [C] - Cancer [C04] | | | | |
CERTITEM, NCT01079143 / 2009-011473-33: Progression of Renal Interstitial Fibrosis / Tubular Atrophy (IF/TA) According to Epithelial-mesenchymal Transition (EMT) and Immunosuppressive Regimen (Everolimus Based Versus CNI Based) in de Novo Renal Transplant Recipients |
|
|
| Completed | 3 | 194 | Europe | Certican®, Everolimus, RAD001, Neoral, Cyclosporine, Myfortic, Simulect®, basiliximab, Corticosteroids | Novartis Pharmaceuticals | Renal Interstitial Fibrosis | 06/12 | 06/12 | | |
NCT01023815 / 2008-007507-83: Once-a-day Regimen With Everolimus, Low Dose Cyclosporine and Steroids in Comparison With Steroid Withdrawal or Twice a Day Regimen With Everolimus, Low Dose Cyclosporine and Steroids. |
|
|
| Completed | 3 | 330 | Europe | everolimus, Certican®), cyclosporine, CsA, Sandimmun® Neoral®, Prednison (continuous steroids) | Novartis | de Novo Kidney Transplant Recipients, Renal Transplantation | 07/12 | 07/12 | | |
NCT00464399: Feasibility and Safety of Early Switch to Everolimus From Cyclosporine in de Novo Renal Transplant Patients |
|
|
| Completed | 3 | 20 | Europe | everolimus | Novartis Pharmaceuticals | De Novo Renal Transplantation | 12/12 | | | |
| Active, not recruiting | 3 | 110 | Japan | everolimus, mycophenolate mofetil | Novartis | Renal Transplant | 12/12 | | | |
| Completed | 3 | 276 | Europe | everolimus, certican, basiliximab, simulect, CNI | Novartis Pharmaceuticals | Liver Transplantation | 01/13 | 01/13 | | |
NCT01025817: Non-inferiority Study of Safety and Efficacy of Everolimus With Low Dose Tacrolimus to Mycophenolate Mofetil With Standard Dose Tacrolimus in Kidney Transplant Recipients |
|
|
| Completed | 3 | 613 | US, Canada | Everolimus and tacrolimus, mycophenolate mofetil and tacrolimus, Active Comparator Control) | Novartis Pharmaceuticals | Kidney Transplant | 03/13 | 03/13 | | |
| Completed | 3 | 284 | US, Europe, RoW | Tacrolimus (reduced tacrolimus), FK-506,, fujimycin,, Prograf,, Advagraf,, Protopic, Everolimus (reduced tacrolimus), RAD001,, Zortress,, Certican,, Afinitor, Tacrolimus (tacrolimus elimination), Everolimus (tacrolimus elimination), Tacrolimus (tacrolimus control), Corticosteroids | Novartis Pharmaceuticals | Liver Transplant Recipient | 05/13 | 05/13 | | |
EVOLVE-1, NCT01035229 / 2009-010196-25: Global Study Looking at the Combination of RAD001 Plus Best Supportive Care (BSC) and Placebo Plus BSC to Treat Patients With Advanced Hepatocellular Carcinoma. |
|
|
| Completed | 3 | 546 | Japan, US, Canada, Europe, RoW | Everolimus, RAD001, Everolimus Placebo, Best Supportive Care (BSC) | Novartis Pharmaceuticals | Carcinoma | 10/13 | 10/13 | | |
|
|
|
MACS2096, NCT01626222 / 2011-006111-62: 4EVER - Efficacy, Safety, Health Economics, Translational Research of Postmenopausal Women With Estrogen Receptor Positive Locally Advanced or Metastatic Breast Cancer |
|
|
| Completed | 3 | 301 | Europe | Exemestane, Everolimus (RAD001) | Novartis Pharmaceuticals | Metastatic Breast Cancer | 11/13 | 11/13 | | |
|
| Completed | 3 | 656 | Japan, US, Canada, Europe, RoW | Everolimus, RAD001, Everolimus placebo, Best Supportive Care (BSC) | Novartis Pharmaceuticals | Advanced Gastric Cancer | 01/14 | 01/14 | | |
|
|
|
|
|
|
| Completed | 3 | 327 | Europe | Anti R-IL2 + Cyclosporine, Thymoglobulin + Everolimus, Anti R-IL2 + Cyclosporine then Everolimus | University Hospital, Brest, Novartis, Roche Pharma AG, Genzyme, a Sanofi Company, Ministry of Health, France | Renal Transplant | 03/14 | 07/14 | | |
2010-022583-13: Otevřené, multicentrické klinické hodnocení pro rozšíření dostupnosti přípravku RAD001 u pacientů se subependymalním obrovskobuněčným astrocytomem (SEGA) spojeným s komplexem tuberózní sklerózy (TSC) |
|
|
| Completed | 3 | 250 | Europe | RAD001 2,5 mg, RAD001, Tablet, Afinitor | Novartis Pharma Services AG, Novartis Farmaceútica S.A., NOVARTIS FARMA, , Novartis Pharma Services AG | The study will evaluate the safety of RAD001 in patients with subependymal giant cell astrocytomas (SEGA) associated with Tuberous Sclerosis Complex (TSC)., Subependymal giant cell astrocytoma (SEGA) associated with Tuberous Sclerosis Complex (TSC), Diseases [C] - Cancer [C04] | | | | |
| Terminated | 3 | 1 | US | Everolimus, Zortress | Ashtar Chami, Novartis Pharmaceuticals | Kidney Failure, Chronic | 05/14 | 05/14 | | |
| Completed | 3 | 719 | Canada, Japan, US, Europe, RoW | Everolimus, RAD001, Placebo, Trastuzumab, Paclitaxel | Novartis Pharmaceuticals | Breast Cancer | 05/14 | 10/17 | | |
Evelyn, NCT01773460: Everolimus Beyond Progress for Patients Who Had Progress Under Everolimus and Exemestane |
|
|
| Terminated | 3 | 3 | Europe | Everolimus, Everolimus, Afinitor, RAD-001, Everolimus-placebo, placebo | German Breast Group, Novartis | Metastatic Breast Cancer | 07/14 | 07/14 | | |
CERTICOEUR, NCT00799188: A Secondary Prevention Study of Skin Cancers in Heart Transplant Patients. Everolimus Versus Calcineurin Inhibitors Multicenter Trial |
|
|
| Unknown status | 3 | 175 | Europe | Everolimus, Certican | Hospices Civils de Lyon | Cardiac Transplantation, Skin Cancer | 09/14 | | | |
| Completed | 3 | 54 | Europe | Everolimus (Afinitor®) | Hopital Foch | Urothelial Cancer | 10/14 | 10/14 | | |
| Completed | 3 | 828 | Europe, RoW | Everolimus, Certican, Zortress, RAD001, Prograf or Neoral, Tacrolimus or Cyclosporine | Novartis Pharmaceuticals | Kidney Transplantation | 10/14 | 10/14 | | |
| Completed | 3 | 302 | Europe, Canada, Japan, US, RoW | Everolimus, RAD001, Placebo, Best suportive care (BSC) | Novartis Pharmaceuticals | Advanced NET of GI Origin, Advanced NET of Lung Origin, Neuroendocrine Tumors | 11/14 | 08/20 | | |
|
|
|
NCT01680861: Tacrolimus/Everolimus Versus Tacrolimus/Enteric-Coated Mycophenolate Sodium |
|
|
| Completed | 3 | 32 | US | Tacrolimus, Prograf (brand name), Everolimus, Zortress (brand name), Enteric Coated Mycophenolate Sodium (EC-MPS), Myfortic (brand name), Corticosteroids, Methylprednisolone | Gaetano Ciancio | Transplant; Failure, Kidney | 12/14 | 12/14 | | |
BOLERO-2, NCT00863655 / 2008-008698-69: Everolimus in Combination With Exemestane in the Treatment of Postmenopausal Women With Estrogen Receptor Positive Locally Advanced or Metastatic Breast Cancer Who Are Refractory to Letrozole or Anastrozole |
 | In combination with exemestane in postmenopausal women with HR+, HER2- adv BC | | Sep 2014 - Sep 2014: In combination with exemestane in postmenopausal women with HR+, HER2- adv BC | | | | Sep 2014 - Sep 2014: | | Quality-adjusted PFS data from the BOLERO-2 trial | | Jul 2014 - Jul 2014: Quality-adjusted PFS data from the BOLERO-2 trial | | EBCC 2014 | | Mar 2014 - Mar 2014: EBCC 2014 | | In postmenopausal women with HR+ve adv BC | | Mar 2014 - Mar 2014: In postmenopausal women with HR+ve adv BC | | EBCC 2014 | | Mar 2014 - Mar 2014: EBCC 2014 | | EBCC 2014 | | Mar 2014 - Mar 2014: EBCC 2014 | | SABCS 2013 | | Jan 2014 - Jan 2014: SABCS 2013 | | In combination with exemestane as first-line therapy in HR+, HER2 - adv BC | | Dec 2013 - Dec 2013: In combination with exemestane as first-line therapy in HR+, HER2 - adv BC | | P3 data- BOLERO-2 | | Dec 2013 - Dec 2013: P3 data- BOLERO-2 | | In combination with exemestane in postmenopausal women with HR+, HER2- adv BC | | Dec 2013 - Dec 2013: In combination with exemestane in postmenopausal women with HR+, HER2- adv BC | | In combination with exemestane in postmenopausal women with HR+, HER2- adv BC | | Nov 2013 - Nov 2013: In combination with exemestane in postmenopausal women with HR+, HER2- adv BC | | In combination with exemestane in postmenopausal women with HR+, HER2- adv BC | | Oct 2013 - Oct 2013: In combination with exemestane in postmenopausal women with HR+, HER2- adv BC | | ESMO-ECCO-ESTRO 2013 | | Sep 2013 - Sep 2013: ESMO-ECCO-ESTRO 2013 | | In combination with exemestane in postmenopausal women with HR+, HER2- adv BC | | Aug 2013 - Aug 2013: In combination with exemestane in postmenopausal women with HR+, HER2- adv BC | | In postmenopausal women with advanced breast cancer | | Jun 2013 - Jun 2013: In postmenopausal women with advanced breast cancer | | ASCO 2013 | | Jun 2013 - Jun 2013: ASCO 2013 | | ASCO 2013 | | May 2013 - May 2013: ASCO 2013 | | SG-BCC 2013 | | Mar 2013 - Mar 2013: SG-BCC 2013 | | SG-BCC 2013 | | Mar 2013 - Mar 2013: SG-BCC 2013 | | SG-BCC 2013 | | Mar 2013 - Mar 2013: SG-BCC 2013 | | Everolimus halts the development of bone metastases that are directly associated with the breast cancer | | Mar 2013 - Mar 2013: Everolimus halts the development of bone metastases that are directly associated with the breast cancer | | AACR-2013 | | Mar 2013 - Mar 2013: AACR-2013 | | BOLERO-2; Bone marker levels and PD data | | Feb 2013 - Feb 2013: BOLERO-2; Bone marker levels and PD data | | BOLERO-2; HER2-, HR+; +/vs. exemestane | | Feb 2013 - Feb 2013: BOLERO-2; HER2-, HR+; +/vs. exemestane | | P3 data: BOLERO-2 (SABCS 2012) | | Dec 2012 - Dec 2012: P3 data: BOLERO-2 (SABCS 2012) | | P3 data-ISPOR Eu | | Nov 2012 - Nov 2012: P3 data-ISPOR Eu | | P3 data- ESMO 2012 | | Sep 2012 - Sep 2012: P3 data- ESMO 2012 | | P3 data- ESMO 2012 | | Sep 2012 - Sep 2012: P3 data- ESMO 2012 | | P3 data - ESMO 2012 | | Sep 2012 - Sep 2012: P3 data - ESMO 2012 | | P3 data - ASCO-BC 2012 | | Sep 2012 - Sep 2012: P3 data - ASCO-BC 2012 | | P3 data - ASCO-BC 2012 | | Sep 2012 - Sep 2012: P3 data - ASCO-BC 2012 | | P3 data - ASCO-BC 2012 | | Sep 2012 - Sep 2012: P3 data - ASCO-BC 2012 | | P3 data - ASCO-BC 2012 | | Sep 2012 - Sep 2012: P3 data - ASCO-BC 2012 | | P3 data - ASCO-BC 2012 | | Sep 2012 - Sep 2012: P3 data - ASCO-BC 2012 | | P3 data - ASCO | | Jun 2012 - Jun 2012: P3 data - ASCO | | P3 data - ASCO | | Jun 2012 - Jun 2012: P3 data - ASCO | | P3 data - ASCO | | Jun 2012 - Jun 2012: P3 data - ASCO | | P3 data - ASCO | | Jun 2012 - Jun 2012: P3 data - ASCO | | P3 data - ASCO | | Jun 2012 - Jun 2012: P3 data - ASCO | | P3 data - IMPAKT | | Apr 2012 - Apr 2012: P3 data - IMPAKT | | Data-ONS | | Apr 2012 - Apr 2012: Data-ONS | | Data-EBCC | | Mar 2012 - Mar 2012: Data-EBCC | | Data-EBCC | | Mar 2012 - Mar 2012: Data-EBCC | | P3 data | | Dec 2011 - Dec 2011: P3 data | | P3 data-SABCS | | Dec 2011 - Dec 2011: P3 data-SABCS | | P3 data | | Dec 2011 - Dec 2011: P3 data | | P3 data | | Sep 2011 - Sep 2011: P3 data | | P3 data | | Jul 2011 - Jul 2011: P3 data | | More | |
|
|
| Completed | 3 | 724 | Japan, US, Canada, Europe, RoW | Everolimus, RAD001, Exemestane, Everolimus Placebo | Novartis Pharmaceuticals | Breast Cancer | 12/14 | 12/14 | | |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
SIMCER, NCT01625377 / 2012-000137-39: A National Multi-center Randomized, Open Label Study to Evaluate Efficacy and Safety of Everolimus With EC-MPS Compared to Standard Treatment Combination Tacrolimus and EC-MPS in de Novo Liver Transplant Recipients |
|
|
| Completed | 3 | 188 | Europe | tacrolimus, Prograf®, everolimus, Certican® / RAD001, Basiliximab, Simulect®, Mycophenolic Acid, Myfortic®, Corticosteroids | Novartis Pharmaceuticals | Liver Transplantation | 03/15 | 03/15 | | |
| Completed | 3 | 821 | Europe, Canada, Japan, US, RoW | Nivolumab, BMS-936558, Everolimus, Afinitor | Bristol-Myers Squibb, Ono Pharmaceutical Co. Ltd | Advanced or Metastatic (Medically or Surgically Unresectable) Clear-cell Renal Cell Carcinoma | 05/15 | 07/21 | | |
|
|
|
|
|
|
|
|
|
|
|
|
| Completed | 3 | 658 | Europe, Canada, US, RoW | Cabozantinib tablets, XL184, Everolimus (Afinitor) tablets | Exelixis | Renal Cell Carcinoma | 05/15 | 01/21 | | |
|
|
|
|
|
|
|
|
|
|
|
|
|
NCT00514514 / 2006-007021-32: Study Investigating a Standard Regimen in de Novo Kidney Transplant Patients Versus a Calcineurin Inhibitor (CNI)-Free Regimen and a CNI-low Dose Regimen |
|
|
| Completed | 3 | 802 | Europe | Everolimus, Certican, Myfortic, Enteric Coated Mycophenolate Sodium, Sandimmun Optoral, Cyclosporine A, Simulect®, Basiliximab | Novartis Pharmaceuticals | Kidney Transplantation | 06/15 | 06/15 | | |
| Completed | 3 | 569 | Japan, US, Europe, RoW | everolimus, RAD001, Placebo, vinorelbine, trastuzumab | Novartis Pharmaceuticals | HER2/Neu Over-expressing Locally Advanced Breast Cancer, Metastatic Breast Cancer | 06/15 | 06/15 | | |
|
|
|
|
|
|
|
NCT02314312: Efficacy and Safety of Everolimus in de Novo Kidney Transplant Recipients of ECD or AKI Donors |
|
|
| Unknown status | 3 | 48 | NA | Everolimus + low dose cyclosporin A + prednisolone, Standard immunosupressive regimen | Mahidol University | Transplantation of Kidney, Expanded Criteria Donor, ECD | 06/15 | 06/15 | | |
| Completed | 3 | 383 | Europe | Everolimus, Certican®, Mycophenolate sodium, Myfortic®, Cyclosporine, Neoral®, Steroids | Novartis Pharmaceuticals | Kidney Transplantation | 12/15 | 12/15 | | |
2009-012436-32: Immunomonitoring by virus-specific T cells and evaluation as a prognostic marker for virus-induced diseases after kidney transplantation |
|
|
| Ongoing | 3 | 64 | Europe | Sandimmun Optoral 10 mg Weichkapseln, Sandimmun Optoral 25 mg Weichkapseln, Sandimmun Optoral 50 mg Weichkapseln, Sandimmun Optoral 100 mg Weichkapseln, Sandimmun® Optoral 100 mg/ml Lösung zum Einnehmen, Certican 0,1 mg Tabletten zur Herstellung einer Suspension zum Einnehmen, Certican 0,25 mg Tabletten zur Herstellung einer Suspension zum Einnehmen, Sandimmun Optoral 10 mg Weichkapseln, Sandimmun Optoral 25 mg Weichkapseln, Sandimmun Optoral 50 mg Weichkapseln, Sandimmun Optoral 100 mg Weichkapseln, Sandimmun® Optoral 100 mg/ml Lösung zum Einnehmen, Certican 0,1 mg Tabletten zur Herstellung einer Suspension zum Einnehmen, Certican 0,25 mg Tabletten zur Herstellung einer Suspension zum Einnehmen | Medizinische Hochschule Hannover | After solid organ transplantation immunosuppressive treatment disrupts the individual balance between virus-replication and cellular immune response. This can lead to an elevated risk of severe viral complications.1) Immunosuppressive therapy might better be steered by measuring of virus-specific T cells than by blood levels of immunosuppressants solely.2) The antiviral treatment should be restricted to patients with high risk of viral diseases (high costs, severe side effects). | | | | |
2005-000380-26: A 12 month, multicenter, randomized, parallel, open-label study, to evaluate renal function and efficacy of Certican® (everolimus) with Simulect® (basiliximab) and cyclosporine discontinuation at 3 month post-transplant vs minimization, in de novo kidney transplant recipients |
|
|
| Ongoing | 3 | 168 | Europe | Certican®, RAD001, Certican®, Certican® | Novartis Farmacéutica S.A. | Renal Transplant | | | | |
2006-001407-11: A single center study investigating ciclosporine A microemulsion in combination with basiliximab and prednisolon and switch to low-dose ciclosporine A and everolimus without steroids in the prevention of transplant nephropathy in pediatric renal allografts recipients. |
|
|
| Completed | 3 | 20 | Europe | Certican, | Medizinische Hochschule Hannover | Kidney transplantation after end stage renal failure | | 05/10 | | |
2005-004908-36: Extension E-03 al Protocolo nº RAD001AB253Estudio de seguimiento de 2 años para obtener datos especificos de la evolución de los pacientes de novo trasplantados cardíacos que discontinuaron la medicación de estudio de forma precoz en el estudio RAD001AB253Extension E-03 to Protocol No. RAD001A B253Tiene también en cuenta la Enmienda nº1 al Protocolo RAD001B253E3 |
|
|
| Ongoing | 3 | 332 | Europe | Certican®, Imurel®, Certican®, Imurel® | Novartis Farmaceútica S.A | Trasplante cardiaco de novo | | | | |
2008-000102-36: Immunosoppressive protocol based on everolimus and calcineurin inhibitor low doses in lung transplant recipients with moderate-severe kidney disease after standard immnuotherapy. |
|
|
| Ongoing | 3 | 20 | Europe | CERTICAN, CERTICAN | OSPEDALE POLICLINICO S. MATTEO | kidney disease after pulmonary transplant | | | | |
2007-006221-27: Immunosuppression without calcineurin inhibitors and with the use of everolimus (Certican) in HCV-infected liver transplant patients |
|
|
| Ongoing | 3 | 50 | Europe | CERTICAN*60CPR 0,75MG, PROGRAF*60CPS 1MG, CERTICAN*60CPR 0,75MG, PROGRAF*60CPS 1MG | AZIENDA OSPEDALIERA DI BOLOGNA POLICLINICO S. ORSOLA M. MALPIGHI | HCV cirrhosis | | | | |
2012-000073-23: An expanded access study for postmenopausal women with estrogen receptor positive locally advanced or metastatic breast cancer who have progressed following prior endocrine therapy, investigating the treatment of everolimus (RAD001) in combination with exemestane |
|
|
| | 3 | 600 | Europe | Everolimus, exemestane, RAD001, Afinitor, Afinitor | Novartis Pharma Services AG, NOVARTIS FARMACEUTICA S.A, NOVARTIS FARMA, Novartis Pharma Services AG, NOVARTIS PHARMA SERVICES AG | Estrogen receptor positive locally advanced or metastatic breast cancer in postmenopausal women | | 09/14 | | |
2012-004856-12: Changes in the immune status (information on the status of the immune system)bei nierentransplantierten Patienten after switch to the immunosuppressive (suppression of immunological processes) therapy on the mTOR inhibitor everolimus (medication which prevent rejection following organ transplantation). An open-label (knowledge of the assigned treatment), non-randomized (no random allocation to treatment groups), single center (contacted in one study center) study. Veränderungen des Immunstatus (Zustand des Immunsystems) bei nierentransplantierten Patienten nach Umstellung der immunsuppressiven (Unterdrückung immunologischer Prozesse) Therapie auf den mTOR Inhibitor Everolimus (Medikament, dass die Abstossungsreaktion nach Organtransplantation verhindern soll). Eine nicht-verblindete (Wissen um die zugeteilte Therapie), nicht-randomisierte (keine zufällige Zuteilung zu den Behandlungsgruppen), monozentrische (in einem Studienzentrum durchgeführt) Studie. |
|
|
| Ongoing | 3 | 40 | Europe | Certican, Tacrolimus Sandoz, Certican 0,25mg Tabletten, Tacrolimus Sandoz 0,5mg Hartkapseln, Certican 0,5mg Tabletten, Certican 0,75mg Tabletten, Certican 1 mg Tabletten, Tacrolimus Sandoz 1mg Hartkapseln, Tacrolimus Sandoz 5mg Hartkapseln, Certican 0,25mg Tabletten, Tacrolimus Sandoz 0,5mg Hartkapseln, Certican 0,5mg Tabletten, Certican 0,75mg Tabletten, Certican 1 mg Tabletten, Tacrolimus Sandoz 1mg Hartkapseln, Tacrolimus Sandoz 5mg Hartkapseln | Medizinische Universität Graz, Universitätsklinik für Innere Medizin, Klinische Abteilung für Nephrologie, Medizinische Universität Graz | organ transplant | | | | |
2012-005397-63: Expanded access study of RAD001 in patient with angiomyolipoma associated with tuberous sclerosis complex (TSC) Estudio de acceso expandido con RAD001 en pacientes con angiomiolipoma asociado a complejo de esclerosis tuberosa (CET) |
|
|
| Completed | 3 | 30 | Europe | everolimus, RAD001, Votubia, Votubia | Novartis Farmacéutica, S.A,, Novartis Farmacéutica,S.A | Angiomyolipoma associated with either Tuberous Sclerosis Complex (TSC) Angiomiolipoma en pacientes con Complejo de Esclerosis Tuberosa (CET) | | | | |
NCT02040584 / 2013-001191-38: A Multicentre, Randomised, Open-label, Controlled, 12-month Follow-up Study to Assess Impact on Renal Function of an Immunosuppression Regimen Based on Tacrolimus Minimisation in Association With Everolimus in de Novo Liver Transplant Recipients. |
|
|
| Completed | 3 | 217 | Europe | Minimisation of TAC, TAC + MMF + corticosteroids | Novartis Pharmaceuticals | Liver Transplant | 02/16 | 02/16 | | |
| Completed | 3 | 612 | Europe | Everolimus, Certican, Tacrolimus, Cyclosporin A, Enteric Coated Mycophenolate Sodium (EC-MPS), Mycophenolate mofetil (MMF), Corticosteroids, Simulect, Basiliximab | Novartis Pharmaceuticals | Kidney Transplantation, Renal Transplantation | 03/16 | 03/16 | | |
2010-018353-36: BeTACTIC Study. Best Therapy After Cardiac Transplantation, the Italian Challenge. A multicenter, prospective, randomized, open-label study to compare the efficacy and safety of Everolimus and Mycophenolate (either mofetil or sodium) in association with Cyclosporine in patients with acute multiple/late rejection, cardiac allograft vasculopathy, renal dysfunction after cardiac transplantation |
|
|
| Ongoing | 3 | 400 | Europe | CERTICAN, CELLCEPT, MYFORTIC, CERTICAN, CELLCEPT, MYFORTIC | AZIENDA OSPEDALIERA OSPEDALE NIGUARDA CA, GRANDA (A.O. DI RILIEVO NAZIONALE) | Paitents will be enrolled at least one year after heart transplant | | | | |
NCT01598987 / 2011-003069-14: Efficacy, Safety and Tolerability of Everolimus in Combination With Reduced Exposure Cyclosporine or Tacrolimus in Paediatric Liver Transplant Recipients. |
|
|
| Completed | 3 | 56 | US, Canada, Europe, RoW | Introduction of everolimus with reduced cyclosporine or tacrolimus dose, the earliest 1 month and the latest 6 months after liver transplantation. | Novartis Pharmaceuticals | Renal Function, Liver Transplant | 06/16 | 06/16 | | |
PILLAR2, NCT00790036 / 2008-000498-40: Phase III Study of RAD001 Adjuvant Therapy in Poor Risk Patients With Diffuse Large B-Cell Lymphoma (DLBCL) of RAD001 Versus Matching Placebo After Patients Have Achieved Complete Response With First-line Rituximab-chemotherapy |
|
|
| Completed | 3 | 742 | Japan, US, Canada, Europe, RoW | Everolimus, RAD001, Everolimus Placebo | Novartis Pharmaceuticals | Diffuse Large B-cell Lymphoma | 06/16 | 06/16 | | |
|
NCT01707849 / 2012-002105-22: The Impact of Everolimus Based Immunosuppression in the Evolution of Hepatitis C Fibrosis After Liver Transplantation |
|
|
| Completed | 3 | 18 | Europe | EVL arm, Everolimus, MMF arm, Mofetil Mycophenolate | Hospital Vall d'Hebron | Hepatitis C Recurrence After Liver Transplant | 08/16 | 08/16 | | |
| Completed | 3 | 78 | Europe | Everolimus, Tacrolimus | Novartis Pharmaceuticals | Liver Transplantation | 09/16 | 09/16 | | |
NCT01544491 / 2010-024381-21: Efficacy, Tolerability and Safety of Early Introduction of Everolimus, Reduced Calcineurin Inhibitors and Early Steroid Elimination Compared to Standard CNI, Mycophenolate Mofetil and Steroid Regimen in Paediatric Renal Transplant Recipients |
|
|
| Completed | 3 | 106 | US, Europe, RoW | RAD001, MMF | Novartis Pharmaceuticals | Prevention of Acute Rejection in Paediatric Recipients of a Renal Transplant | 10/16 | 09/18 | | |
| Completed | 3 | 285 | Canada, Japan, US, Europe, RoW | Everolimus + reduced tacrolimus, Standard tacrolimus | Novartis Pharmaceuticals | Liver Transplantation | 10/16 | 04/18 | | |
| Completed | 3 | 130 | Europe | standard therapy, Everolimus, RAD001 | Novartis Pharmaceuticals | Lung Transplantation | 01/17 | 01/17 | | |
| Completed | 3 | 300 | Europe | Paclitaxel, RAD001, Everolimus, Certican | Krankenhaus Nordwest | Advanced Gastric Cancer, Esophagogastric Junction Cancer | 07/17 | 10/19 | | |
EXIST-3, NCT01713946 / 2011-000860-90: A Placebo-controlled Study of Efficacy & Safety of 2 Trough-ranges of Everolimus as Adjunctive Therapy in Patients With Tuberous Sclerosis Complex (TSC) & Refractory Partial-onset Seizures |
|
|
| Completed | 3 | 366 | Canada, Japan, US, Europe, RoW | RAD001, everolimus, Placebo, Antiepileptic drug (1 to 3 only), open label RAD001 (only used for post-extension phase), open label everolimus | Novartis Pharmaceuticals | Tuberous Sclerosis Complex-associated Refractory Seizures | 10/17 | 10/17 | | |
EVERKYSTE, NCT02134899: The Efficacy of Everolimus in Reducing Total Native Kidney Volume in Polycystic Kidney Disease Transplanted Recipients |
|
|
| Completed | 3 | 3 | Europe | Everolimus, everolimus conversion, Calcineurin inhibitors maintenance, calcineurin-inhibitors based immunosuppression | Assistance Publique - Hôpitaux de Paris, Novartis | Autosomal Dominant Polycystic Kidney Disease | 11/17 | 11/17 | | |
NCT01198158: Everolimus With or Without Bevacizumab in Treating Patients With Advanced Kidney Cancer That Progressed After First-Line Therapy |
|
|
| Terminated | 3 | 77 | US | Bevacizumab, Anti-VEGF, Anti-VEGF Humanized Monoclonal Antibody, Anti-VEGF rhuMAb, Avastin, Bevacizumab Biosimilar BEVZ92, Bevacizumab Biosimilar BI 695502, Bevacizumab Biosimilar CBT 124, Bevacizumab Biosimilar FKB238, Bevacizumab Biosimilar MIL60, Bevacizumab Biosimilar QL 1101, BEVACIZUMAB, LICENSE HOLDER UNSPECIFIED, Immunoglobulin G1 (Human-Mouse Monoclonal rhuMab-VEGF Gamma-Chain Anti-Human Vascular Endothelial Growth Factor), Disulfide With Human-Mouse Monoclonal rhuMab-VEGF Light Chain, Dimer, Recombinant Humanized Anti-VEGF Monoclonal Antibody, rhuMab-VEGF, Everolimus, 42-O-(2-Hydroxy)ethyl Rapamycin, Afinitor, Certican, RAD 001, RAD001, Votubia, Zortress, Laboratory Biomarker Analysis, Pharmacological Study | National Cancer Institute (NCI) | Clear Cell Renal Cell Carcinoma, Recurrent Renal Cell Carcinoma, Stage III Renal Cell Cancer AJCC v7, Stage IV Renal Cell Cancer AJCC v7 | 12/17 | 12/17 | | |
|
| Unknown status | 3 | 745 | Europe | Everolimus, Afinitor, Exemestane, Aromasin, Fulvestrant, Faslodex | Consorzio Oncotech, Clinical Research Technology S.r.l. | Metastatic Breast Cancer, Breast Cancer, Hormone Receptor Positive Tumor, Human Epidermal Growth Factor 2 Negative Carcinoma of Breast, Locally Advanced Malignant Neoplasm | 01/18 | 01/19 | | |
NCT02376985: Evaluation of Oral Care to Prevent Oral Mucositis in ER Positive MBC Patients Treated With Everolimus: Phase 3 RCT |
|
|
| Completed | 3 | 174 | Japan | Oral management, Everolimus | Comprehensive Support Project for Oncology Research, Novartis Pharmaceuticals | Breast Cancer | 03/18 | 10/18 | | |
CIME, NCT01595984: Comparison of Efficacy and Safety of Treatment With a Calcineurin Inhibitor (CNI)Versus a CNI-free Treatment in Renal Transplantation |
|
|
| Unknown status | 3 | 90 | Europe | cyclosporin + mycophenolate mofetil, everolimus + mycophenolate mofetil | Centre Hospitalier Universitaire, Amiens, Novartis | Kidney Failure | 08/18 | 08/18 | | |
EVEREXES, NCT03176238: Study in Post-menopausal Women With Hormone Receptor Positive, HER2-negative Advanced Breast Cancer |
|
|
| Completed | 3 | 235 | RoW | everolimus, RAD001, exemestane | Novartis Pharmaceuticals | Post Menopausal Breast Cancer | 01/19 | 01/19 | | |
NCT02334488: Study Evaluating the Benefit of Two Immunosuppressive Strategies on Renal Function |
|
|
| Completed | 3 | 329 | Europe | Everolimus, Certican®, Tacrolimus, Prograg®, Mycophenolate sodium, Myfortic® | Poitiers University Hospital | Chronic Kidney Disease | 05/19 | 07/20 | | |
NCT02137837: S1222 Trial (Everolimus, Anastrozole and Fulvestrant) in Post-Menopausal Stage IV Breast Cancer |
|
|
| Terminated | 3 | 37 | US | Fulvestrant, Faslodex, NSC-719276, Anastrozole, Arimidex, NSC-719344, Everolimus, Afinitor, Zortress, NSC-733504, Placebo - Anastrozole, Placebo - Everolimus | Southwest Oncology Group, AstraZeneca, Novartis | Breast Cancer | 12/19 | 12/19 | | |
| Completed | 3 | 110 | Europe | Everolimus, Aromatase Inhibitors, Exemestane, Letrozole, Anastrozole | Istituto Oncologico Veneto IRCCS, University of Padova | Breast Cancer Metastatic | 02/20 | 07/20 | | |
REACH3, NCT03112603 / 2016-004432-38: A Study of Ruxolitinib vs Best Available Therapy (BAT) in Patients With Steroid-refractory Chronic Graft vs. Host Disease (GvHD) After Bone Marrow Transplantation |
|
|
| Completed | 3 | 330 | Europe, Canada, Japan, US, RoW | Ruxolitinib, Jakafi, INCB018424, Extracorporeal photopheresis (ECP), Low-dose methotrexate (MTX), Mycophenolate mofetil (MMF), mechanistic Target of Rapamycin (mTOR) inhibitors (everolimus or sirolimus), Infliximab, Rituximab, Pentostatin, Imatinib, Ibrutinib | Incyte Corporation | Graft-versus-host Disease (GVHD) | 05/20 | 12/22 | | |
|
|
UNIRAD, NCT01805271 / 2012-003187-44: Safety Study of Adding Everolimus to Adjuvant Hormone Therapy in Women With High Risk of Relapse, ER+ and HER2- Primary Breast Cancer, Free of Disease After Receiving at Least One Year of Adjuvant Hormone Therapy |
|
|
| Active, not recruiting | 3 | 1278 | Europe | Everolimus, Afinitor, Placebo | UNICANCER, Ministry of Health, France | Primary Non-metastatic Breast Cancer, Who Remain Disease-free | 06/20 | 06/30 | | |
NCT04258423: Everolimus Plus Mycophenolic Acid for Kidney Preservation in Liver Transplant Recipients With Impaired Kidney Function |
|
|
| Terminated | 3 | 4 | US | Tacrolimus, Prograf, Everolimus, Zortress | Indiana University | Kidney Failure | 06/20 | 06/20 | | |
NCT04063865: Everolimus Monotherapy as Immunosuppression After Liver Transplant |
|
|
| Terminated | 3 | 14 | US | Tacrolimus, Prograf, Everolimus, Zortress | Indiana University | Kidney Failure | 07/20 | 07/20 | | |
| Active, not recruiting | 3 | 1069 | Europe, Canada, Japan, US, RoW | Lenvatinib, Everolimus, Pembrolizumab, Sunitinib | Eisai Inc., Merck Sharp & Dohme LLC | Renal Cell Carcinoma | 08/20 | 07/24 | | |
|
|
|
|
|
|
|
|
|
| Completed | 3 | 141 | Europe | Drug: Everolimus, Afinitor, STZ-5FU, STZ based Chemotherapy | Grupo Espanol de Tumores Neuroendocrinos, European Neuroendocrine Tumor Society, Kantar Health, Novartis Pharmaceuticals | Neuroendocrine Tumors | 11/20 | 07/21 | | |
| Withdrawn | 3 | 0 | NA | TAC withdrawal, Everolimus with reduced TAC | Novartis Pharmaceuticals | Liver Transplantation | 12/20 | 12/20 | | |
MIST, NCT03839940: Dexamethasone in Reducing Everolimus-Induced Oral Stomatitis in Patients With Cancer |
|
|
| Terminated | 3 | 39 | US | Dexamethasone, Placebo, Questionnaire, Quality-of-Life Assessment, Everolimus | Alliance for Clinical Trials in Oncology, National Cancer Institute (NCI) | Malignant Neoplasm | 12/20 | 12/20 | | |
| Active, not recruiting | 3 | 390 | RoW | CM082 combined with everolimus, X-82, Affinitor, CM082, Everolimus | AnewPharma | Renal Cell Cancer Metastatic | 02/21 | 12/21 | | |
NCT02909335: De Novo Everolimus Versus Tacrolimus in Combination With Mofetil Mycophenolate and Low Dose Corticosteroids to Reduce Tacrolimus Induced Nephrotoxicity in Liver Transplantation: a Prospective, Multicentric, Randomised Study |
|
|
| Withdrawn | 3 | 0 | NA | Tacrolimus, Prograf, Everolimus, Certican, Mycophenolate mofetil, Cellcept, Prednisolone, Prednisone or Methylprednisolone, Methylprednisolone: Solumedrol®, Prednisolone: Solupred®, Prednisone: Cortancyl® | Rennes University Hospital | Liver Transplantation | 11/21 | 11/21 | | |
S1207, NCT01674140: Hormone Therapy With or Without Everolimus in Treating Patients With Breast Cancer |
|
|
| Active, not recruiting | 3 | 1939 | US | anastrozole, Arimidex, everolimus, Afinitor, exemestane, Aromasin, goserelin acetate, Zoladex, letrozole, Femara, leuprolide acetate, Lupron, tamoxifen citrate, nolvadex, placebo | SWOG Cancer Research Network, National Cancer Institute (NCI) | Breast Cancer | 12/22 | 01/30 | | |
NCT03580239: Everolimus in Castrated Resistant Prostate Cancer(CRPC)Patients With PI3K-AKT-mTOR Signaling Pathway Deficiency |
|
|
| Not yet recruiting | 3 | 120 | RoW | Everolimus, Novartis Pharma Schweiz AG, Placebo | Tianjin Medical University Second Hospital, Tianjin Medical University General Hospital, Tianjin First Central Hospital, The Second Affiliated Hospital of Tianjin University of Traditional Chinese Medicine，China | Prostate Cancer | 01/23 | 12/23 | | |
TEAMMATE, NCT03386539: Tacrolimus/Everolimus vs. Tacrolimus/MMF in Pediatric Heart Transplant Recipients Using the MATE Score |
|
|
| Active, not recruiting | 3 | 211 | US | Everolimus, Zortress, Tacrolimus, Prograf, Mycophenolate Mofetil, Cellcept | Boston Children's Hospital, Stanford University, United States Department of Defense | Pediatric Heart Transplantation, Immunosuppression, Chronic Kidney Diseases, Cardiac Allograft Vasculopathy, Heart Transplant Failure and Rejection, Post-transplant Lymphoproliferative Disorder, Heart Transplant Infection | 04/23 | 01/24 | | |
